Galderma Expands Restylane Portfolio in Japan With Launch of OBT Hyaluronic Acid Injectables Restylane Defyne and Refyne

Restylane Refyne and Restylane Defyne are the first Optimal Balance Technology (OBT) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2
This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4
These two new launches underscore Galderma’s accelerating growth across the Japan & Asia Pacific (JPAC) region

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBTbased hyaluronic acid injectables ever authorized in Japan.1,2 The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.1,2

Restylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma’s proprietary OBT – designed to move in harmony with facial expressions while maintaining shape and lift – and are the first and only hyaluronic acid injectables clinically proven to restore youthful facial expressions.1,2,5-11 Restylane Refyne offers a smooth, flexible gel, ideal for delicate, highly expressive areas, while Restylane Defyne provides support for areas such as the jawline and deeper facial folds.1,2,5-11 These launches mark a major milestone for Galderma and represent an important chapter in its JPAC growth strategy, supporting the company’s continuing expansion in one of the region’s most dynamic aesthetics markets.